Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free FBLG Stock Alerts

FibroBiologics (FBLG) Financials

FibroBiologics logo
$1.47 +0.06 (+4.26%)
As of 03:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for FibroBiologics

Annual Income Statements for FibroBiologics

This table shows FibroBiologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.12 -19 -8.97 -19
Consolidated Net Income / (Loss)		 -5.12 -16 -11 -19
Net Income / (Loss) Continuing Operations		 -5.12 -16 -8.97 -19
Total Pre-Tax Income 		-5.12 -16 -8.97 -18
Total Operating Income		 -4.47 -8.89 -14 -17
Total Gross Profit		 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 4.47 8.89 14 17
Selling, General & Admin Expense		 3.32 6.52 9.23 9.24
Research & Development Expense		 1.15 2.37 4.50 7.41
Total Other Income / (Expense), net		 -0.65 -7.38 2.58 -1.38
Interest Expense		 0.65 0.15 0.02 0.20
Interest & Investment Income		 - 0.00 0.25 0.25
Other Income / (Expense), net		 0.00 -7.24 4.54 -1.42
Other Gains / (Losses), net		 - -0.21 - -0.62
Basic Earnings per Share		 ($0.18) ($0.68) ($0.34) ($0.42)
Weighted Average Basic Shares Outstanding		 28.23M 28.23M 32.88M 44.66M
Diluted Earnings per Share		 ($0.18) ($0.68) ($0.34) ($0.42)
Weighted Average Diluted Shares Outstanding		 28.23M 28.23M 32.88M 44.66M
Weighted Average Basic & Diluted Shares Outstanding		 - 32.63M 37.74M 67.59M

Quarterly Income Statements for FibroBiologics

This table shows FibroBiologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Total Costs & Expenses		 - - - - - - - - - 5.07 4.03
Net Income / (Loss) Attributable to Common Shareholders		 -9.72 -8.46 1.80 0.00 -2.30 0.00 0.00 0.00 -9.02 0.00 0.00
Consolidated Net Income / (Loss)		 -9.72 -8.46 2.40 -0.50 -4.60 -4.97 -4.66 -5.78 -3.24 -5.00 -4.12
Net Income / (Loss) Continuing Operations		 -9.72 -8.46 2.40 -0.50 -2.40 -4.97 -4.66 -5.78 -3.87 -5.00 -4.12
Total Pre-Tax Income 		-9.56 -8.46 2.40 -0.50 -2.40 -4.97 -4.03 -5.78 -3.25 -5.00 -4.12
Total Operating Income		 -2.48 -3.45 -3.22 -3.35 -3.71 -4.53 -4.49 -5.04 -2.59 -5.07 -4.03
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 2.48 3.45 3.22 3.35 3.71 4.53 4.49 5.04 2.59 5.07 4.03
Selling, General & Admin Expense		 1.71 2.49 2.25 2.14 2.36 2.75 2.45 2.25 1.79 2.12 2.38
Research & Development Expense		 0.77 0.96 0.98 1.21 1.36 1.78 2.04 2.79 0.80 2.95 1.66
Total Other Income / (Expense), net		 -7.08 -5.01 5.62 2.85 -0.89 -0.44 0.46 -0.74 -0.66 0.07 -0.08
Interest Expense		 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.20 0.00 0.01
Interest & Investment Income		 - 0.04 0.07 0.08 0.06 0.10 0.05 0.07 0.03 0.02 0.02
Other Income / (Expense), net		 -7.08 -5.05 5.56 2.78 1.25 -0.53 0.41 -0.81 -0.48 0.05 -0.09
Basic Earnings per Share		 ($0.34) ($0.27) $0.03 ($0.01) ($0.09) ($2.71) ($2.41) ($0.13) ($0.03) ($1.33) ($0.66)
Weighted Average Basic Shares Outstanding		 28.23M 31.13M 32.72M 33.52M 32.88M 1.83M 1.93M 43.07M 44.66M 3.77M 6.27M
Diluted Earnings per Share		 ($0.34) ($0.27) $0.03 ($0.01) ($0.09) ($2.71) ($2.41) ($0.13) ($0.03) ($1.33) ($0.66)
Weighted Average Diluted Shares Outstanding		 28.23M 31.13M 32.72M 33.52M 32.88M 1.83M 1.93M 43.07M 44.66M 3.77M 6.27M
Weighted Average Basic & Diluted Shares Outstanding		 32.63M 32.72M 35.16M 34.66M 37.74M 38.26M 41.89M 51.46M 67.59M 5.21M 6.66M

Annual Cash Flow Statements for FibroBiologics

This table details how cash moves in and out of FibroBiologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.86 6.90 4.82 -9.09
Net Cash From Operating Activities		 -4.07 -6.40 -12 -16
Net Cash From Continuing Operating Activities		 -4.07 -6.40 -12 -16
Net Income / (Loss) Continuing Operations		 -5.12 -16 -11 -19
Consolidated Net Income / (Loss)		 -5.12 -16 -11 -19
Depreciation Expense		 0.00 0.05 0.16 0.24
Amortization Expense		 0.48 0.47 0.42 1.21
Non-Cash Adjustments To Reconcile Net Income		 0.27 9.21 -2.01 4.11
Changes in Operating Assets and Liabilities, net		 0.31 0.35 0.70 -3.31
Net Cash From Investing Activities		 0.00 -0.50 -0.18 -0.26
Net Cash From Continuing Investing Activities		 0.00 -0.50 -0.18 -0.26
Purchase of Property, Plant & Equipment		 0.00 -0.50 -0.18 -0.26
Net Cash From Financing Activities		 5.93 14 17 7.57
Net Cash From Continuing Financing Activities		 5.93 14 17 7.57
Repayment of Debt		 -0.53 0.30 -0.57 -3.40
Issuance of Debt		 4.30 0.00 9.97 4.38
Issuance of Common Equity		 - 0.00 7.51 6.59
Cash Interest Paid		 0.00 0.00 0.02 0.20
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for FibroBiologics

This table details how cash moves in and out of FibroBiologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -1.60 -1.01 -3.69 3.35 6.16 -5.32 0.18 -3.35 0.03 -3.41 2.03
Net Cash From Operating Activities		 -1.60 -4.28 -1.95 -2.61 -3.07 -5.28 -3.98 -3.97 -3.16 -4.36 -3.29
Net Cash From Continuing Operating Activities		 -1.60 -4.28 -3.45 -1.11 -3.07 -5.28 -3.98 -3.35 -3.16 -4.36 -3.29
Net Income / (Loss) Continuing Operations		 -9.72 -8.46 0.90 -0.50 -3.10 -4.97 -4.66 -5.78 -3.24 -5.00 -4.12
Consolidated Net Income / (Loss)		 -9.72 -8.46 0.90 -0.50 -3.10 -4.97 -4.66 -5.78 -3.24 -5.00 -4.12
Depreciation Expense		 0.03 0.04 0.04 0.04 0.05 0.05 0.06 0.07 0.07 0.07 0.07
Amortization Expense		 0.10 0.10 0.10 0.11 0.11 0.11 0.77 0.79 0.17 0.17 0.10
Non-Cash Adjustments To Reconcile Net Income		 7.94 5.49 -5.06 -0.73 -1.71 1.09 0.32 1.77 1.18 0.64 -1.13
Changes in Operating Assets and Liabilities, net		 0.05 -1.44 0.58 -0.02 1.58 -1.56 -0.48 -0.19 -1.34 -0.24 1.80
Net Cash From Financing Activities		 - 3.28 -0.17 4.47 9.33 0.00 4.38 - 3.19 0.95 5.32
Net Cash From Continuing Financing Activities		 - 3.28 -0.17 4.47 9.33 0.00 4.38 - 3.19 0.95 5.32
Repayment of Debt		 - -0.12 -0.17 -0.17 -0.12 0.00 - - -3.40 -0.08 -0.12
Issuance of Common Equity		 - 2.82 - 4.64 0.05 0.00 - - 6.59 0.71 5.45
Cash Interest Paid		 0.00 0.00 - 0.01 0.01 0.00 0.01 - 0.20 0.00 0.00

Annual Balance Sheets for FibroBiologics

This table presents FibroBiologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 4.82 12 16 9.62
Total Current Assets		 2.63 9.22 14 6.35
Cash & Equivalents		 2.27 9.16 14 4.89
Prepaid Expenses		 0.03 0.04 0.23 1.46
Other Current Assets		 0.03 0.02 0.02 0.00
Plant, Property, & Equipment, net		 0.00 0.80 0.82 0.84
Total Noncurrent Assets		 2.20 1.81 1.39 2.43
Other Noncurrent Operating Assets		 2.20 1.81 1.39 2.43
Total Liabilities & Shareholders' Equity		 4.82 12 16 9.62
Total Liabilities		 8.82 11 14 3.46
Total Current Liabilities		 7.07 9.18 13 1.76
Short-Term Debt		 5.45 0.00 9.17 0.00
Accounts Payable		 0.76 1.44 2.70 0.95
Other Current Liabilities		 0.86 7.74 0.86 0.81
Total Noncurrent Liabilities		 1.75 1.39 0.98 1.70
Other Noncurrent Operating Liabilities		 1.75 1.39 0.98 1.70
Total Equity & Noncontrolling Interests		 -4.00 1.25 2.74 6.16
Total Preferred & Common Equity		 -4.00 1.25 2.74 6.16
Preferred Stock		 0.00 0.00 0.00 0.00
Total Common Equity		 -4.00 1.25 2.74 6.16
Common Stock		 2.42 26 38 60
Retained Earnings		 -7.87 -24 -36 -54

Quarterly Balance Sheets for FibroBiologics

This table presents FibroBiologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 11 8.91 10 11 14 8.74 5.94 7.93
Total Current Assets		 8.92 6.51 8.20 9.33 10 5.24 2.91 5.85
Cash & Equivalents		 8.16 5.97 7.83 8.67 8.85 4.87 1.48 3.52
Prepaid Expenses		 0.75 0.52 0.35 0.64 1.33 0.37 1.02 0.53
Other Current Assets		 0.02 0.02 0.02 0.02 0.00 0.00 0.40 1.81
Plant, Property, & Equipment, net		 0.77 0.80 0.77 0.81 0.97 0.91 0.78 0.71
Total Noncurrent Assets		 1.71 1.60 1.50 1.29 2.76 2.60 2.26 1.37
Other Noncurrent Operating Assets		 1.71 1.60 1.50 1.29 2.76 2.60 2.26 1.37
Total Liabilities & Shareholders' Equity		 11 8.91 10 11 14 8.74 5.94 7.93
Total Liabilities		 15 11 7.73 9.08 13 8.62 3.34 3.29
Total Current Liabilities		 14 10 6.68 8.21 11 6.72 1.83 2.21
Short-Term Debt		 0.46 0.29 0.12 5.84 8.07 4.57 0.25 0.12
Accounts Payable		 0.81 1.21 1.18 1.42 1.80 1.07 0.85 1.82
Other Current Liabilities		 13 8.64 5.38 0.96 1.10 1.08 0.73 0.27
Total Noncurrent Liabilities		 1.28 1.17 1.06 0.87 2.08 1.90 1.51 1.08
Other Noncurrent Operating Liabilities		 1.28 1.17 1.06 0.87 2.08 1.90 1.51 1.08
Total Equity & Noncontrolling Interests		 -3.86 -2.39 2.74 2.35 0.86 0.13 2.60 4.64
Total Preferred & Common Equity		 -3.86 -2.39 2.74 2.35 0.86 0.13 2.60 4.64
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -3.86 -2.39 2.74 2.35 0.86 0.13 2.60 4.64
Common Stock		 29 30 35 43 46 51 62 68
Retained Earnings		 -33 -32 -32 -40 -45 -51 -59 -63

Annual Metrics And Ratios for FibroBiologics

This table displays calculated financial ratios and metrics derived from FibroBiologics' official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 34,659,125.00 51,456,077.00
DEI Adjusted Shares Outstanding		 0.00 0.00 34,659,125.00 51,456,077.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.26 -0.36
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -291.74% 44.74% -92.64%
EBIT Growth		 0.00% -260.98% 42.96% -96.48%
NOPAT Growth		 0.00% -98.99% -54.54% -21.20%
Net Income Growth		 0.00% -221.91% 32.30% -67.06%
EPS Growth		 0.00% -277.78% 50.00% -23.53%
Operating Cash Flow Growth		 0.00% -57.43% -85.92% -37.75%
Free Cash Flow Firm Growth		 0.00% 0.00% -1,861.59% 2.89%
Invested Capital Growth		 0.00% -875.34% 73.68% 160.61%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 45.23% 9.26%
EBIT Q/Q Growth		 0.00% 0.00% 43.57% 8.20%
NOPAT Q/Q Growth		 0.00% 0.00% -9.85% 6.31%
Net Income Q/Q Growth		 0.00% 0.00% 31.44% 6.77%
EPS Q/Q Growth		 0.00% 0.00% 42.37% 12.50%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -14.11% -0.55%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 13.03%
Invested Capital Q/Q Growth		 0.00% 0.00% 58.15% 846.75%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 101.31% 124.48% 103.43%
Interest Burden Percent		 114.64% 100.91% 97.49% 99.76%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 128.15% 1,201.97% -559.73% -419.44%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,188.45%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 128.15% 1,201.97% -559.73% -419.44%
Return on Equity Simple (ROE_SIMPLE)		 128.15% -1,315.64% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.13 -6.22 -9.62 -12
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 62.61% -343.35% -22.10% -144.00%
Return On Investment Capital (ROIC_SIMPLE)		 - -496.59% -80.79% -189.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.47 -16 -9.20 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.98 -16 -8.62 -17
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 115.07 25.34 1.88
Price to Tangible Book Value (P/TBV)		 0.00 115.07 25.34 1.88
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 5.29
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 154.01 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 -1.36 0.00 3.35 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 -0.80 2.18 -3.51 -1.09
Leverage Ratio		 -1.21 -6.07 7.09 2.93
Compound Leverage Factor		 -1.38 -6.12 6.91 2.92
Debt to Total Capital		 374.64% 0.00% 77.02% 0.00%
Short-Term Debt to Total Capital		 374.64% 0.00% 77.02% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -274.64% 100.00% 22.98% 100.00%
Debt to EBITDA		 -1.37 0.00 -1.06 0.00
Net Debt to EBITDA		 -0.80 0.00 0.56 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.74 0.00 -0.95 0.00
Net Debt to NOPAT		 -1.02 0.00 0.50 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 3.36 0.80 -1.73 -11.50
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.37 1.00 1.12 3.61
Quick Ratio		 0.36 1.00 1.10 2.78
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.88 -15 -15
Operating Cash Flow to CapEx		 0.00% -1,293.13% -6,467.93% -6,257.25%
Free Cash Flow to Firm to Interest Expense		 0.00 5.96 -772.20 -73.52
Operating Cash Flow to Interest Expense		 -6.22 -43.54 -595.05 -80.36
Operating Cash Flow Less CapEx to Interest Expense		 -6.22 -46.91 -604.25 -81.65
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 -0.81 -7.91 -2.08 1.26
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -7.10 5.83 3.34
Enterprise Value (EV)		 147 135 65 6.68
Market Capitalization		 144 144 69 12
Book Value per Share		 ($0.14) $0.04 $0.08 $0.12
Tangible Book Value per Share		 ($0.14) $0.04 $0.08 $0.12
Total Capital		 1.46 1.25 12 6.16
Total Debt		 5.45 0.00 9.17 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 3.19 -9.16 -4.82 -4.89
Capital Expenditures (CapEx)		 0.00 0.50 0.18 0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.26 -9.13 -3.32 -0.30
Debt-free Net Working Capital (DFNWC)		 1.00 0.03 11 4.59
Net Working Capital (NWC)		 -4.45 0.03 1.50 4.59
Net Nonoperating Expense (NNE)		 1.99 10 1.55 6.99
Net Nonoperating Obligations (NNO)		 3.19 -9.16 -4.82 -4.89
Total Depreciation and Amortization (D&A)		 0.48 0.52 0.57 1.46
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.68) ($0.34) ($0.42)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 28.23M 32.88M 44.66M
Adjusted Diluted Earnings per Share		 $0.00 ($0.68) ($0.34) ($0.42)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 28.23M 32.88M 44.66M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 32.63M 37.74M 67.59M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.13 -6.22 -9.62 -12
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -6.83 -109.69 -459.85 -88.58
NOPAT to Interest Expense		 -4.78 -42.33 -480.80 -57.13
EBIT Less CapEx to Interest Expense		 -6.83 -113.06 -469.05 -89.86
NOPAT Less CapEx to Interest Expense		 -4.78 -45.70 -490.00 -58.41
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for FibroBiologics

This table displays calculated financial ratios and metrics derived from FibroBiologics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 0.00 32,634,366.00 32,719,125.00 35,159,125.00 34,659,125.00 37,735,300.00 38,262,586.00 41,889,142.00 51,456,077.00 67,594,722.00 5,208,915.00
DEI Adjusted Shares Outstanding		 0.00 32,634,366.00 32,719,125.00 35,159,125.00 34,659,125.00 1,886,765.00 1,913,129.00 41,889,142.00 51,456,077.00 3,379,736.00 5,208,915.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.26 0.05 0.00 -0.07 0.00 0.00 0.00 -0.18 0.00 0.00
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -296.87% 224.21% 79.19% 75.54% 41.33% -231.50% -1,053.58% -23.03% 2.55% -21.89%
EBIT Growth		 0.00% -272.59% 211.47% 73.73% 74.28% 40.38% -275.01% -915.80% -24.89% 0.97% -1.03%
NOPAT Growth		 0.00% -52.32% -120.05% -63.35% -49.70% -31.33% 2.51% -50.30% 30.21% -11.85% 10.18%
Net Income Growth		 0.00% -250.31% 211.02% 77.20% 52.67% 41.30% -294.25% -1,055.60% 29.46% -0.68% 11.61%
EPS Growth		 0.00% -50.00% 137.50% 87.50% 73.53% 41.30% -294.25% -1,200.00% 66.67% 50.92% 72.61%
Operating Cash Flow Growth		 0.00% -109.97% -19.82% -128.80% -91.94% -23.39% -104.62% -52.42% -2.93% 17.27% 17.39%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -255.85% -332.98% -417.00% 38.79% 62.19% 64.71%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 73.68% 95.87% 101.00% 96.60% 160.61% 385.36% 1,437.04%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -353.10% 11.36% 129.59% -117.51% -432.56% -112.66% 33.69% -28.84% 43.20% -68.45% 17.05%
EBIT Q/Q Growth		 -335.89% 11.13% 127.46% -124.69% -326.91% -105.98% 19.39% -43.30% 47.51% -63.33% 17.76%
NOPAT Q/Q Growth		 -20.81% -39.17% -33.50% 27.22% -10.71% -22.10% 0.90% -12.20% 48.59% -95.68% 20.42%
Net Income Q/Q Growth		 -343.09% 12.94% 128.35% -120.85% -819.80% -7.98% 6.20% -24.04% 43.86% -54.13% 17.66%
EPS Q/Q Growth		 -325.00% 20.59% 111.11% -133.33% -800.00% -7.98% 6.20% -8.33% 76.92% -4,333.33% 50.38%
Operating Cash Flow Q/Q Growth		 -40.56% -167.02% 54.46% -33.85% -17.92% -71.66% 24.47% 0.30% 20.37% -37.97% 24.59%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -46.99% -45.79% -420.54% -69.19% 20.75% 26.24% 38.11% -4.51% 26.02%
Invested Capital Q/Q Growth		 0.00% -46.17% 30.18% 38.37% 58.15% 77.04% 116.95% -308.64% 846.75% 8.08% -8.72%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 101.63% 100.00% 100.00% 99.60% 191.47% 100.00% 115.50% 100.00% 99.82% 100.00% 100.00%
Interest Burden Percent		 100.02% 99.59% 102.79% 87.15% 97.68% 98.05% 98.78% 98.75% 105.83% 99.68% 99.81%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 1,201.97% 583.23% 752.91% -594.78% -559.73% 1,013.48% 1,928.36% -1,397.69% -419.44% -754.75% -660.08%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -23,966.42% 0.00% -1,188.45% -1,017.02% -1,941.83%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 1,201.97% 583.23% 752.91% -594.78% -559.73% 1,013.48% 1,928.36% -1,397.69% -419.44% -754.75% -660.08%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 583.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.74 -2.42 -3.22 -2.35 -2.60 -3.17 -3.14 -3.53 -1.81 -3.55 -2.82
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -87.11% -157.03% 197.75% 47.88% -28.63% -34.09% -46.87% -56.24% -29.47% -71.48% -62.06%
Return On Investment Capital (ROIC_SIMPLE)		 -138.49% 70.95% 153.52% -82.27% -21.82% -38.73% -35.21% -75.07% -29.45% -124.65% -59.31%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.56 -8.50 2.33 -0.58 -2.46 -5.07 -4.08 -5.85 -3.07 -5.02 -4.13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.43 -8.36 2.47 -0.43 -2.31 -4.90 -3.25 -5.00 -2.84 -4.78 -3.96
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 115.07 0.00 0.00 39.69 25.34 14.45 27.68 183.04 1.88 1.72 1.06
Price to Tangible Book Value (P/TBV)		 115.07 0.00 0.00 39.69 25.34 14.45 27.68 183.04 1.88 1.72 1.06
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 284.30 0.00 5.29 2.36 1.24
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 -0.12 -0.12 0.04 3.35 2.48 9.38 36.58 0.00 0.09 0.03
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -7.31 1.99 2.38 -2.82 -3.51 6.96 4.23 -2.80 -1.09 -0.82 -0.76
Leverage Ratio		 -6.07 -2.95 -3.73 3.83 7.09 -15.09 -14.94 6.71 2.93 3.51 3.97
Compound Leverage Factor		 -6.07 -2.94 -3.84 3.33 6.92 -14.79 -14.76 6.63 3.10 3.50 3.97
Debt to Total Capital		 0.00% -13.48% -13.67% 4.03% 77.02% 71.30% 90.37% 97.34% 0.00% 8.64% 2.61%
Short-Term Debt to Total Capital		 0.00% -13.48% -13.67% 4.03% 77.02% 71.30% 90.37% 97.34% 0.00% 8.64% 2.61%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 113.48% 113.67% 95.97% 22.98% 28.70% 9.63% 2.66% 100.00% 91.36% 97.40%
Debt to EBITDA		 0.00 -0.02 -0.02 -0.01 -1.06 -1.13 -0.74 -0.25 0.00 -0.01 -0.01
Net Debt to EBITDA		 0.00 0.35 0.33 0.49 0.56 0.55 0.07 0.02 0.00 0.08 0.20
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.07 -0.04 -0.01 -0.95 -0.56 -0.72 -0.37 0.00 -0.02 -0.01
Net Debt to NOPAT		 0.00 1.09 0.72 0.88 0.50 0.27 0.07 0.02 0.00 0.10 0.29
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.64 6.85 4.03 4.09 -0.37 -4.06 -4.49 -8.97 -6.36 -15.72 -11.44
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.00 0.64 0.64 1.23 1.12 1.14 0.93 0.78 3.61 1.59 2.64
Quick Ratio		 1.00 0.58 0.59 1.17 1.10 1.06 0.81 0.72 2.78 0.81 1.59
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 9.15 4.85 2.63 -8.43 -14 -11 -8.33 -5.16 -5.39 -3.99
Operating Cash Flow to CapEx		 -80,050.00% -53,437.50% -2,950.00% -23,690.91% -3,104.04% -12,267.44% -1,870.42% -66,200.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 2,286.75 969.80 525.72 -1,404.28 0.00 0.00 0.00 -25.28 -1,347.40 -569.59
Operating Cash Flow to Interest Expense		 -800.50 -1,068.75 -389.40 -521.20 -512.17 0.00 0.00 0.00 -15.50 -1,091.00 -470.14
Operating Cash Flow Less CapEx to Interest Expense		 -801.50 -1,070.75 -402.60 -523.40 -528.67 0.00 0.00 0.00 -15.50 -1,091.00 -470.14
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -7.91 -12 -8.07 -4.98 -2.08 -0.48 0.08 -0.17 1.26 1.36 1.25
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -12 -8.07 -4.98 5.83 11 8.15 4.81 3.34 1.84 1.16
Enterprise Value (EV)		 135 345 158 101 65 31 23 23 6.68 3.23 1.55
Market Capitalization		 144 353 163 109 69 34 24 23 12 4.46 4.94
Book Value per Share		 $0.04 ($0.12) ($0.07) $0.08 $0.08 $0.07 $0.02 $0.00 $0.12 $0.69 $0.89
Tangible Book Value per Share		 $0.04 ($0.12) ($0.07) $0.08 $0.08 $0.07 $0.02 $0.00 $0.12 $0.69 $0.89
Total Capital		 1.25 -3.40 -2.10 2.85 12 8.19 8.93 4.70 6.16 2.85 4.76
Total Debt		 0.00 0.46 0.29 0.12 9.17 5.84 8.07 4.57 0.00 0.25 0.12
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -9.16 -7.70 -5.69 -7.71 -4.82 -2.83 -0.78 -0.29 -4.89 -1.24 -3.39
Capital Expenditures (CapEx)		 0.00 0.01 0.07 0.01 0.10 0.04 0.21 0.01 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.13 -13 -9.31 -6.19 -3.32 -1.71 -1.57 -1.78 -0.30 -0.16 0.25
Debt-free Net Working Capital (DFNWC)		 0.03 -4.60 -3.34 1.64 11 6.96 7.28 3.09 4.59 1.32 3.76
Net Working Capital (NWC)		 0.03 -5.06 -3.62 1.52 1.50 1.12 -0.79 -1.48 4.59 1.08 3.64
Net Nonoperating Expense (NNE)		 7.98 6.05 -5.62 -1.85 2.00 1.79 1.52 2.25 1.43 1.45 1.29
Net Nonoperating Obligations (NNO)		 -9.16 -7.70 -5.69 -7.71 -4.82 -2.83 -0.78 -0.29 -4.89 -1.24 -3.39
Total Depreciation and Amortization (D&A)		 0.13 0.14 0.14 0.14 0.15 0.16 0.83 0.86 0.23 0.24 0.16
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.34) ($0.27) $0.03 ($0.01) ($0.09) ($2.80) ($2.40) ($0.13) ($0.03) ($1.33) ($0.66)
Adjusted Weighted Average Basic Shares Outstanding		 28.23M 31.13M 32.72M 33.52M 32.88M 1.83M 1.93M 43.07M 44.66M 3.77M 6.27M
Adjusted Diluted Earnings per Share		 ($0.34) ($0.27) $0.03 ($0.01) ($0.09) ($2.80) ($2.40) ($0.13) ($0.03) ($1.33) ($0.66)
Adjusted Weighted Average Diluted Shares Outstanding		 28.23M 31.13M 32.72M 33.52M 32.88M 1.83M 1.93M 43.07M 44.66M 3.77M 6.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 32.63M 32.72M 35.16M 34.66M 37.74M 1.91M 2.09M 51.46M 67.59M 5.21M 6.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.74 -2.42 -2.26 -2.35 -2.60 -3.17 -3.14 -3.53 -1.81 -3.55 -2.82
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4,779.50 -2,123.75 466.60 -115.20 -409.83 0.00 0.00 0.00 -15.05 -1,254.00 -589.29
NOPAT to Interest Expense		 -867.65 -603.75 -644.80 -469.28 -432.95 0.00 0.00 0.00 -8.89 -886.90 -403.30
EBIT Less CapEx to Interest Expense		 -4,780.50 -2,125.75 453.40 -117.40 -426.33 0.00 0.00 0.00 -15.05 -1,254.00 -589.29
NOPAT Less CapEx to Interest Expense		 -868.65 -605.75 -658.00 -471.48 -449.45 0.00 0.00 0.00 -8.89 -886.90 -403.30
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

FibroBiologics (NASDAQ:FBLG) remains a pre-revenue biotechnology company with persistent operating losses and negative operating cash flow. Across the reported periods from the third quarter of 2023 through the second quarter of 2026, revenue was consistently reported at zero. The company’s financial profile therefore continues to depend on research progress and access to external financing rather than internally generated sales.

  • Quarterly loss narrowed in Q2 2026. Net loss improved to $4.1 million from $5.0 million in Q1 2026 and $4.7 million in Q2 2025. The basic and diluted loss per share improved to $0.66 from $1.33 in the prior quarter, although changing share counts make per-share comparisons less consistent.
  • Operating expenses declined. Total operating expenses fell to $4.0 million in Q2 2026 from $5.1 million in Q1 2026 and $4.5 million in Q2 2025. Research and development spending declined sequentially to $1.7 million from $3.0 million, while selling, general and administrative expense increased modestly to $2.4 million.
  • Operating cash burn improved sequentially. Net cash used in operating activities was $3.3 million in Q2 2026, compared with $4.4 million in Q1 2026 and $4.0 million in Q2 2025. This suggests some near-term improvement in cash consumption, though the company has not yet approached positive operating cash flow.
  • Liquidity increased during the second quarter. Cash and equivalents rose to $3.5 million at June 30, 2026, from $1.5 million at March 31, 2026. The increase was primarily funded by $5.4 million of net financing cash flow, including $5.4 million from common-equity issuance.
  • Balance-sheet leverage improved substantially from mid-2025. Total liabilities declined to $3.3 million at June 30, 2026, from $13.0 million at June 30, 2025. Short-term debt also fell to $124,000 from $8.1 million over the same period, reducing financial leverage and interest burden.
  • Current assets exceeded current liabilities at the latest quarter. Total current assets were $5.9 million versus $2.2 million of current liabilities, implying a current ratio of approximately 2.6. However, cash represented only $3.5 million of current assets, and the company continues to consume several million dollars of cash each quarter.
  • Research spending remains volatile. R&D expense increased from $571,000 in Q3 2023 to $3.0 million in Q1 2026 before falling to $1.7 million in Q2 2026. Lower spending can reduce cash burn, but it may also reflect changes in development activity rather than a durable improvement in efficiency.
  • FibroBiologics has not generated revenue in the reported periods. With no sales or gross profit, operating expenses translate directly into operating losses. A meaningful improvement in the investment case will likely require clinical, regulatory or commercial progress that can eventually support revenue generation.
  • Operating cash flow has remained negative throughout the period provided. Quarterly cash used in operations ranged from approximately $1.1 million to $5.3 million, and Q2 2026 still produced a $3.3 million outflow. At the latest quarterly burn rate, reported cash alone would provide limited funding without additional financing or spending reductions.
  • External financing and dilution remain important risks. Common-equity issuance supplied $5.4 million in Q2 2026, following additional equity financing in earlier periods. Weighted-average basic shares also changed sharply across quarters, from 1.8 million in Q1 2024 to 6.3 million in Q2 2026 and substantially higher figures in certain 2025 periods, indicating that investors should monitor future share issuance and potential dilution carefully.

Overall, the latest quarter showed better expense control, a smaller net loss and a stronger liability position. Nevertheless, FBLG’s core financial trend remains speculative: the company has no reported revenue, continues to lose money, and relies on financing to fund operations. The key metrics for investors to watch are cash runway, future equity issuance, R&D spending and evidence that the company is moving toward clinical or commercial milestones capable of producing revenue.

08/27/26 02:37 PM ETAI Generated. May Contain Errors.

FibroBiologics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, FibroBiologics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

FibroBiologics' net income appears to be on an upward trend, with a most recent value of -$18.65 million in 2025, rising from -$5.12 million in 2022. The previous period was -$11.16 million in 2024. Check out FibroBiologics' forecast to explore projected trends and price targets.

FibroBiologics' total operating income in 2025 was -$16.65 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $16.65 million

Over the last 3 years, FibroBiologics' total revenue changed from $0.00 in 2022 to $0.00 in 2025, a change of 0.0%.

FibroBiologics' total liabilities were at $3.46 million at the end of 2025, a 74.7% decrease from 2024, and a 60.7% decrease since 2022.

In the past 3 years, FibroBiologics' cash and equivalents has ranged from $2.27 million in 2022 to $13.99 million in 2024, and is currently $4.89 million as of their latest financial filing in 2025.

Over the last 3 years, FibroBiologics' book value per share changed from -0.14 in 2022 to 0.12 in 2025, a change of -184.5%.


Related Companies

Financial statements for NASDAQ:FBLG last updated on 8/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...
Decentralized Masters | Sponsoredtc pixel